<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771888</url>
  </required_header>
  <id_info>
    <org_study_id>NL16194.091.07</org_study_id>
    <nct_id>NCT00771888</nct_id>
  </id_info>
  <brief_title>Open-Label Extension of LOCKCYST Trial</brief_title>
  <acronym>LOCKCYST-ext</acronym>
  <official_title>Open-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lnareotide as as Volume Reducing Treatment of Polycystic Livers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Positive data originating from two polycystic liver patients treated with somatostatin
      analogues, showed a volume reduction of 38.3% and 14.9%. These two patients had complicated
      polycystic livers and no other therapeutic options were available.

      Patients who participated in LOCKCYST trial are able to benefit from active treatment.
      Participants will be actively treated for 24 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      van Keimpema L, de Man RA, Drenth JP. Somatostatin analogues reduce liver volume in
      polycystic liver disease. Gut 2008 September;57(9):1338-9.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver volume reduction</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney volume Cyst volume</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Polycystic Liver Disease</condition>
  <condition>Hepatomegaly</condition>
  <condition>Liver Diseases</condition>
  <condition>Polycystic Kidney</condition>
  <condition>Autosomal Dominant</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>lanreotide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lanreotide</intervention_name>
    <description>lanreotide</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participated in the LOCKCYST trial

          -  18 yrs-of age

          -  Multiple cysts &gt; 20

          -  Cooperating patient

          -  Is willing and able to comply with the study drug regimen and all other study
             requirements.

          -  Willingness to give written informed consent

        Exclusion Criteria:

          -  Use of oral anticonceptives or estrogen suppletion

          -  Females who are pregnant or breast-feeding

          -  History or other evidence of chronic pulmonary disease associated with functional
             limitation

          -  History of severe cardiac disease (eg, NYHA Functional Class III or IV, myocardial
             infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment,
             unstable angina or other significant cardiovascular diseases). In addition, patients
             with documented or presumed coronary artery disease or cerebrovascular disease should
             not be enrolled.

          -  History or other evidence of severe illness or any other conditions which would make
             the patient, in the opinion of the investigator, unsuitable for the study

          -  Symptomatic gallstones (lanreotide decreases gall bladder volume)

          -  Renal failure requiring hemodialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joost PH Drenth, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederik Nevens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Gasthuisberg, University of Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loes van Keimpema, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg, University of Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>van Keimpema L, de Man RA, Drenth JP. Somatostatin analogues reduce liver volume in polycystic liver disease. Gut. 2008 Sep;57(9):1338-9. doi: 10.1136/gut.2008.155721.</citation>
    <PMID>18719151</PMID>
  </reference>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2008</study_first_submitted>
  <study_first_submitted_qc>October 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <last_update_submitted>November 12, 2008</last_update_submitted>
  <last_update_submitted_qc>November 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Radboud University Nijmegen Medical Center</name_title>
    <organization>Radboud University Nijmegen Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Cysts</mesh_term>
    <mesh_term>Hepatomegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

